Chardan Capital Maintains Buy on 4D Molecular Therapeutics, Lowers Price Target to $25
Benzinga Newsdesk 3 weeks ago
Analyst RatingsNewsPrice Target
Chardan Capital analyst Gautam Chukka maintains 4D Molecular Therapeutics (NASDAQ:FDMT) with a Buy and lowers the price target from $26 to $25.
Chardan Capital analyst Gautam Chukka maintains 4D Molecular Therapeutics (NASDAQ:FDMT) with a Buy and lowers the price target from $26 to $25.